ArticleCancer chemotherapy and pharmacology2011

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

Anthony W Tolcher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.